Marshall Wace, LLP Jounce Therapeutics, Inc. Transaction History

Marshall Wace, LLP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$2.8 - $7.67 $110,149 - $301,730	39,339 New	39,339 $119,000
Q4 2021 Feb 14, 2022	SELL	$7.11 - $9.64 $1.21 Million - $1.64 Million	-169,686 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$5.04 - $8.73 $412,231 - $714,044	-81,792 Reduced 32.52%	169,686 $1.26 Million
Q2 2021 Aug 13, 2021	BUY	$6.58 - $10.66 $1.03 Million - $1.67 Million	156,739 Added 165.44%	251,478 $1.71 Million
Q1 2021 May 17, 2021	BUY	$6.73 - $13.87 $637,593 - $1.31 Million	94,739 New	94,739 $973,000
Q3 2020 Nov 16, 2020	SELL	$4.58 - $10.95 $386,410 - $923,840	-84,369 Closed	0 $0
Q2 2020 Aug 13, 2020	SELL	$4.17 - $7.58 $716,280 - $1.3 Million	-171,770 Reduced 67.06%	84,369 $582,000
Q1 2020 May 15, 2020	SELL	$2.91 - $8.7 $632,709 - $1.89 Million	-217,426 Reduced 45.91%	256,139 $1.22 Million
Q4 2019 Feb 14, 2020	BUY	$2.81 - $9.21 $1.33 Million - $4.36 Million	473,565 New	473,565 $4.13 Million
Q1 2019 May 14, 2019	SELL	$3.43 - $6.87 $89,176 - $178,613	-25,999 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$2.69 - $6.71 $69,937 - $174,453	25,999 New	25,999 $88,000

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.